As of 2025-07-15, the EV/EBITDA ratio of 10X Genomics Inc (TXG) is -7.97. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TXG's latest enterprise value is 1,158.37 mil USD. TXG's TTM EBITDA according to its financial statements is -145.29 mil USD. Dividing these 2 quantities gives us the above TXG EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.6x - 16.3x | 15.3x |
| Forward P/E multiples | 18.1x - 19.7x | 18.8x |
| Fair Price | (18.27) - (16.19) | (17.03) |
| Upside | -246.5% - -229.9% | -236.5% |
| Date | EV/EBITDA |
| 2025-07-15 | -8.07 |
| 2025-07-14 | -7.97 |
| 2025-07-11 | -8.25 |
| 2025-07-10 | -8.10 |
| 2025-07-09 | -7.66 |
| 2025-07-08 | -7.79 |
| 2025-07-07 | -7.51 |
| 2025-07-03 | -8.43 |
| 2025-07-02 | -8.43 |
| 2025-07-01 | -7.63 |
| 2025-06-30 | -7.22 |
| 2025-06-27 | -7.35 |
| 2025-06-26 | -7.32 |
| 2025-06-25 | -7.29 |
| 2025-06-24 | -6.63 |
| 2025-06-23 | -6.55 |
| 2025-06-20 | -6.57 |
| 2025-06-18 | -6.62 |
| 2025-06-17 | -6.35 |
| 2025-06-16 | -6.74 |
| 2025-06-13 | -6.23 |
| 2025-06-12 | -6.37 |
| 2025-06-11 | -6.54 |
| 2025-06-10 | -6.43 |
| 2025-06-09 | -5.96 |
| 2025-06-06 | -5.39 |
| 2025-06-05 | -5.13 |
| 2025-06-04 | -5.32 |
| 2025-06-03 | -5.13 |
| 2025-06-02 | -5.41 |
| 2025-05-30 | -5.48 |
| 2025-05-29 | -5.32 |
| 2025-05-28 | -4.91 |
| 2025-05-27 | -4.68 |
| 2025-05-23 | -4.33 |
| 2025-05-22 | -4.64 |
| 2025-05-21 | -4.46 |
| 2025-05-20 | -5.10 |
| 2025-05-19 | -4.97 |
| 2025-05-16 | -5.36 |
| 2025-05-15 | -5.20 |
| 2025-05-14 | -5.13 |
| 2025-05-13 | -5.58 |
| 2025-05-12 | -5.45 |
| 2025-05-09 | -4.84 |
| 2025-05-08 | -4.72 |
| 2025-05-07 | -4.45 |
| 2025-05-06 | -4.27 |
| 2025-05-05 | -4.70 |
| 2025-05-02 | -4.55 |